Day: June 10, 2022

PALO ALTO, Calif., June 10, 2022 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and its affiliate company Venthera, Inc. (Venthera), today announced preliminary data from the Phase 1b trial of VT30 topical gel (BBP-681) in patients with venous, lymphatic and mixed venolymphatic lesions of the skin (VM, LM and VLM, respectively), which are rare genetic vascular anomalies driven by dysregulated activation of intracellular PI3K. The data are being shared in a virtual presentation to the International Society for the Study of Vascular Anomalies (ISSVA). “People living with cutaneous VMs and LMs can experience clinical complications including pain, bleeding, and impaired functioning of the affected area. To date, their treatment options are limited to interventional procedures and surgeries. We are pleased that...

Figure 1 Twin Hills Gold Project Main Mineralized Zones (Bulge, Twin Hills Central, Clouds and Twin Hills West)Figure 2 Location of THW drill collars and recent assay results superimposed on ground magnetic image.Figure 3 Section 1 through Twin Hills West, showing at least two zones of mineralization.Figure 4 Section 2 through Twin Hills West, showing wide zones of mineralization.HighlightsLatest drill assays from infill and step-out drilling at Twin Hills West (“THW”) include:OKR497: 5m @ 10.11g/t (170-175m) and 20m @ 1.03g/t (188-208m) OKD413: 40m @ 1.66g/t (43-83m) incl. 21m @ 2.66g/t OKR451: 28m @ 1.64g/t (103-131m) and 5m @ 0.69g/t (202-207m) OKR470: 42m @ 1.10g/t (126-168m) incl. 6m @ 1.36g/t and 26 @ 1.41g/t OKR476: 13m @ 3.41g/t (60-73m) OKR455: 41m @ 0.92g/t (70-111m) incl. 31m @ 1.14g/t OKR466: 34m @ 0.95g/t...

TAMPA, FL, June 10, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – B2Digital Incorporated (the “Company” or “B2Digital”) (OTCMKTS:BTDG), the premier development league for mixed martial arts (“MMA”), is excited to announce that the B2 Fighting Series is now available on the FITE streaming media platform, with past B2FS events becoming available on the FITE+ subscription service beginning yesterday, June 9, and new fight nights appearing on FITE as live pay-per-view (PPV) events, beginning tomorrow, Saturday, June 11, when the B2 Fighting Series heads back to Birmingham, Alabama for a hard hitting night of MMA action at B2FS 165. What: B2 Fighting Series 165, Amateur and Professional LIVE MMA Where: Bill Harris Arena in Birmingham, Alabama When: Saturday, June 11. Doors open at 6 pm ET. PPV Broadcast starts at 7 pm ET on FITE+ Physical...

— Breakthrough Therapy Designations granted for ROS1-positive non-small cell lung cancer (NSCLC) patients pretreated with one prior line of ROS1 tyrosine kinase inhibitor (TKI) with or without prior chemotherapy — Potential best-in-class therapy for ROS1-positive metastatic NSCLC and NTRK-positive advanced solid tumors SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted two Breakthrough Therapy Designations for investigational repotrectinib for the treatment of patients with ROS1-positive metastatic NSCLC who have received one prior line of ROS1...

PHILADELPHIA, June 10, 2022 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that The Nasdaq Stock Market LLC (“Nasdaq”) notified the Company on June 9, 2022 that Nasdaq has determined the Company has regained compliance with the requirements to remain listed in The Nasdaq Capital Market, as required by a hearing panel’s decision dated May 4, 2022, subject to a one-year Mandatory Panel Monitor of the Company’s ongoing compliance with such requirements. On May 31, 2022, the Company filed a Form 6-K (the “Filing”) with the SEC, including unaudited financial statements, and referencing the receipt of proceeds from the sale of the Company’s ordinary...

VANCOUVER, British Columbia, June 10, 2022 (GLOBE NEWSWIRE) — ESE Entertainment Inc. (“ESE” or the “Company”) (TSXV: ESE) (OTCQB: ENTEF) is pleased to announce that its Digital Motorsports brand will be exhibiting at the Crescent Street Grand Prix Festival on June 16 to 18, 2022, during the Formula 1 Canadian Grand Prix. Since 1999, the historic festival has taken place on Crescent Street in downtown Montreal and is the epicenter for race fans during the Grand Prix week. Digital Motorsports will showcase their latest F1-inspired simulators on two separate activation sites right in the heart of crescent street. A total of four professional grade simulators will be linked via computer servers, enabling fans to race against each other on the virtual Circuit De Gilles Villeneuve racetrack in the latest F1-inspired cars. Daily time...

Tegningsperioden for udbud af afdelingen Indeks High Yield Obligationer i Investeringsforeningen PFA Invest er afsluttet den 9. juni 2022 kl. 16.00.Resultatet blev følgende:PFA Invest afdeling ISIN-kode Antal investorer Antal andele stk. Formue i kr.Indeks High Yield Obligationer DK0061804424 1 9.940.358 1.000.000.014,80PFA Pension, forsikringsaktieselskab har tegnet for 1.000.000.014,80 kr. kr. i afdelingen og indgår som investor i ovenstående resultat af tegningen. Andele i afdelingerne var udbudt til tegningskurs 100,60. Andele i afdelingen forventes optaget til handel på NASDAQ Copenhagen A/S den 14. juni 2022. Med venlig hilsenPFA Asset Management A/S Rasmus BessingDirektør          

NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia NUC-7738 Kills AML Cells Resistant to Standard Chemotherapy Data Indicates Potential Clinical Utility Beyond Solid Tumors EDINBURGH, United Kingdom, June 10, 2022 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) announced data to be presented at the European Hematology Association (EHA) 2022 Hybrid Congress highlighting the activity of NUC-7738, a phosphoramidate transformation of 3’-deoxyadenosine (3’-dA), in a broad range of Acute Myeloid Leukemia (AML) cell lines. NUC-7738 has already shown promise as monotherapy in patients with solid tumors in a Phase 1/2 study (NuTide:701) and will also be combined with a PD-1 checkpoint inhibitor. The data at EHA 2022 show that NUC-7738 can suppress the expansion and survival of AML cells by reducing β-catenin signaling,...

WATERTOWN, Mass., June 10, 2022 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that a late-breaking abstract highlighting 12-month data from the Phase 1 DAVIO clinical trial evaluating EYP-1901 for the treatment of wet age-related macular degeneration (wet AMD) has been selected for presentation at the American Society of Retinal Specialists (ASRS) 2022 Annual Meeting to be held in New York City from July 13 – 16, 2022. Presentation details are as follows: Presentation Title: 12-Month Results of EYP-1901 Vorolanib in a Bioerodible Durasert® Insert for nAMD: The DAVIO TrialSession Title: Wet AMD 2 SymposiumDate and Time: Friday, July 15, 2022 at 8:00...

Posters provide background information and trial designs for ongoing clinical studies of wholly-owned NX-2127 and NX-5948 programs SAN FRANCISCO, June 10, 2022 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the company will present clinical trial design details for two of its wholly-owned investigative therapies, NX-2127 and NX-5948, each currently in Phase 1 development, at the EHA2022 Hybrid Congress. The meeting is being held from June 9-12, 2022 in Vienna, Austria and virtually. Poster and presentation details are included below: Title: A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Oral BTK Degrader With Immunomodulatory Activity, in Patients With Relapsed and Refractory B-Cell Malignancies...